Biotech | August 09, 2021
Novavax and Serum Institute submits Emergency Use Authorisation of vaccine to regulatory agencies in India, Indonesia and the Philippines
Filing for WHO Emergency Use Authorisation this month
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Advances deployment of mRNA technology across vaccines and therapeutics development
Deal for 100 million doses with additional 100 million through 2023
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Subscribe To Our Newsletter & Stay Updated
